about
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsMaintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazineHuman anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trialThe CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease.Vedolizumab as induction and maintenance therapy for Crohn's disease.Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases.6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis.The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review.Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.Biosimilars: A Multidisciplinary Perspective.Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases.Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis.Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences.Inflammatory bowel disease as a risk factor for colorectal cancer.Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.Absence of nocturnal acid breakthrough in Helicobacter pylori-positive subjects treated with twice-daily omeprazole.Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study.A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD?CYP7A1 promoter polymorphism -203A>C affects bile salt synthesis rate in patients after ileal resection.Polymorphisms of the TPMT gene in the Czech healthy population and patients with inflammatory bowel disease.Fatal myelotoxicity after azathioprine treatment.A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.Improved HPLC analysis of serum 7alpha-hydroxycholest-4-en-3-one, a marker of bile acid malabsorption.Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs.A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers.What is the time for surgery in severe Crohn's disease?Mutation analysis of the MYH gene in unrelated Czech APC mutation-negative polyposis patients.Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicinesGenetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European ProjectInfliximab dependency is related to decreased surgical rates in adult Crohnʼs disease patientsInfliximab dependency in children with Crohn’s disease
P50
Q22242050-50DA4B2B-C4A0-4070-9924-5C1BA04407BBQ24685766-350E5617-0F41-4DA6-A94E-A6EB62A412E7Q28296771-82712C1E-D32C-4B0C-BCB8-A65EC3EDE8ABQ33600367-89C2C98D-8DC6-4A02-BBF3-6C0AC242591AQ34365574-C7E33EE4-344D-4428-86FA-3A2DDB0013C9Q35038880-965F2CE4-72AE-41AF-9778-6C84AA5E3262Q36403174-15DF3CC3-C434-4433-97A8-F2B05F3D0991Q37240622-270DBBEB-E624-4419-8BBB-432596BD51E5Q37387994-F48AABA8-92CD-4253-BF56-9BC590AD44D5Q37455645-0F676830-B768-4B85-851E-1B14ECBDFDC6Q37859956-011CCCB7-177F-41B0-BBCA-AF54511A4FD0Q38764554-15044D37-2A7B-40B9-AA99-3D9CF3738458Q38778909-CE74281C-CD76-4405-8E9D-829750CC0D88Q39120032-20921EE9-DE35-415D-834E-C7185B375C86Q39366732-0283C035-D935-43A9-BB09-097651398008Q39906288-532B4340-D88A-4006-917A-38DB57046440Q42211914-87764BE6-A782-479A-9FD5-97B287CA3E9BQ42800608-8334CB51-C274-4A43-AC0F-4656F515E5BBQ44696806-BC25BF99-B97B-417E-904B-BCDA7428AA26Q44851359-55AB509D-62D3-4DC0-B9F0-F8C769D7765AQ44854180-414A77BF-E885-48A6-951A-644668B39F19Q45234771-A9A9F4B8-3FA6-4860-8C48-BB423515A495Q45243739-4D3D46CA-187C-4996-9D67-8EF49512F665Q45976650-91FB4470-FC3F-49DD-98C3-C215E7C5B5BBQ46095235-64A84953-56B3-40A8-B5C3-2CEB85BF046DQ46410501-3C3BCB64-90E5-4D95-9448-066141A3CCD2Q46502194-4B3AC427-CCBA-4EEB-BF36-D3566218B008Q46502266-4B9C4E3D-333D-4FD6-9D2B-9157EF1B2E15Q46554729-5831248E-0A5C-4F78-9067-FD96E0A1D97BQ46570526-DCB719D2-D769-4B95-B151-506F613239BFQ46588293-99E37858-B21F-4AE3-8E98-0C4FF73B4CD3Q46944787-8ABC8DCC-3712-4C85-8180-63EE58DE6E4DQ50495588-0BAA74F4-8060-4A9B-BB01-BF715B7F4CAAQ51639717-061A9BB1-0BF9-44AC-A0F7-46D52F176B7DQ53129704-F0D6D1FA-C826-4D93-9262-C6213F417348Q54440826-66D7801D-A34E-482A-B1AF-42904133F88BQ57089307-45EE8E42-68DF-4F8F-8675-0A6A179033BEQ57265321-4F6D9E53-E985-4971-A9AA-8E35CF07F8B0Q57807124-90E09451-09B1-44BE-A601-B194A2689970Q57807157-EFA0B717-A121-4CED-B8EE-C34F48D8E5DD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Milan Lukas
@ast
Milan Lukas
@en
Milan Lukas
@es
Milan Lukas
@nl
Milan Lukas
@sl
type
label
Milan Lukas
@ast
Milan Lukas
@en
Milan Lukas
@es
Milan Lukas
@nl
Milan Lukas
@sl
altLabel
Lukas M.
@en
Lukáš Milan
@en
prefLabel
Milan Lukas
@ast
Milan Lukas
@en
Milan Lukas
@es
Milan Lukas
@nl
Milan Lukas
@sl
P1053
J-6382-2017
P106
P1153
55496043500
P21
P31
P3829
P496
0000-0002-1463-3840